A new agreement with Moderna will see Lonza add three more production lines at its site in Visp, Switzerland. Additional production lines will come online sequentially, said the contract development and manufacturing organization (CDMO). All three are expected to be operational in the earlier part of 2022 In May 2020, Lonza and Moderna announced a 10-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-19 vaccine and additional products from the US biotech in the future. Since then, Lonza has installed three production lines at its Visp (CH) site and one further production line in Portsmouth in the US. Production in Visp (CH) commenced within eight months of the initial agreement.